Real-life data on the efficacy and safety of letermovir for cytomegalovirus prophylaxis in high-risk pediatric patients: a single-center analysis. (PubMed, Transl Pediatr) - Sep 16, 2025 - "LET can effectively prevent CMV reactivation in patients under 18 years of age and demonstrates good safety. For pediatric patients at high risk of CMV reactivation, extending the duration of prophylaxis beyond 100 days may be beneficial."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Pediatrics • Transplantation
|
|
Chenguang Jia; Guanghua Zhu; Jie Zheng; Jun Yang; Lixiao Cai; Maoquan Qin; Meng Zhang; Ningning Chen; Pan Zhang; Wei Yang; Yanhui Luo; Yuanfang Jing
|